RxDoctor Payments Data

William Johnston, MD

Colon & Rectal Surgery · New Orleans, LANPI 1598908253

Payments from drug & device makers

What this record shows

This record is dominated by education: $9,650 of the $14,628 with a category attached, or 66.0%. Intuitive Surgical accounts for 73.3% of it on its own, with 16 other manufacturers making up the rest.

$14,628in general payments, 2019–2025

Across 43 payments — averaging $340.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$11K
  • Lumendi LLC$830
  • Johnson & Johnson$601
  • Applied Medical Resources Corporation$500
  • Medtronic$309
  • Axonics, Inc.$280
  • plus $1K from 11 others

What the payments were for

  • Consulting fees$5003%
  • Travel & lodging$1,65111%
  • Food & beverage$2,82719%
  • Education$9,65066%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,628 in reported general payments places this provider in the 75th percentile of 39 colon & rectal surgery providers in Louisiana.

See all colon & rectal surgery providers in Louisiana

Medicare billing

Part B allowed, 2024
$64,238
Medicare patients
143
Services billed
308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide31$24,838
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates56$3,655
ClenpiqSod Picosulf/Mag Ox/Citric Ac11$1,860
Lubiprostone16$1,526
LoperamideLoperamide Hcl11$1,160
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl41$650
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl36$625
Hydrocortisone60$570
Pantoprazole Sodium24$341
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl16$261
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$160
Metronidazole32$98
Gabapentin14$94
Oxycodone Hcl20$93
Ciprofloxacin Hcl34$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ferring Pharmaceuticals Inc.Clenpiq$37$1,86011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 39 colon & rectal surgery providers in Louisiana.

Other colon & rectal surgery in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →